107 related articles for article (PubMed ID: 33978973)
1. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
2. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
Aliment Pharmacol Ther; 2024 May; ():. PubMed ID: 38695095
[TBL] [Abstract][Full Text] [Related]
3. Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World.
de Ávila Machado MA; de Moura CS; Klein M; Winthrop K; Carleton B; Abrahamowicz M; Feld J; Curtis JR; Beauchamp ME; Bernatsky S
J Manag Care Spec Pharm; 2019 Jun; 25(6):697-704. PubMed ID: 31134863
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
Indolfi G; Easterbrook P; Giometto S; Malik F; Chou R; Lucenteforte E
Liver Int; 2024 Mar; 44(3):663-681. PubMed ID: 38293756
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
6. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
9. Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?
Zarębska-Michaluk D; Flisiak R; Janczewska E; Berak H; Mazur W; Janocha-Litwin J; Krygier R; Dobracka B; Jaroszewicz J; Parfieniuk-Kowerda A; Dobrowolska K; Rzymski P
Antiviral Res; 2023 Dec; 220():105742. PubMed ID: 37944825
[TBL] [Abstract][Full Text] [Related]
10. Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Jay JS; Patterson JA; Zhang Y; Ijioma SC; Carroll NV; Holdford DA; Sterling RK; Gupta G; Yakubu I
J Am Pharm Assoc (2003); 2023; 63(6):1700-1705.e4. PubMed ID: 37414279
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
[TBL] [Abstract][Full Text] [Related]
12. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
Liu CH; Chang YP; Lee JY; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Lee FJ; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
J Med Virol; 2024 May; 96(5):e29675. PubMed ID: 38746997
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life.
Pugliese N; Polverini D; Arcari I; De Nicola S; Colapietro F; Masetti C; Ormas M; Ceriani R; Lleo A; Aghemo A
Trop Med Infect Dis; 2023 Nov; 8(11):. PubMed ID: 37999621
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma.
Garza KY; Pandey A; Marzinke MA
J Pharm Biomed Anal; 2023 Oct; 235():115629. PubMed ID: 37619293
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
[TBL] [Abstract][Full Text] [Related]
16. Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study.
Pawlowska M; Dobrowolska K; Moppert J; Pokorska-Śpiewak M; Purzynska M; Marczynska M; Zarebska-Michaluk D; Flisiak R
J Clin Med; 2023 Nov; 12(21):. PubMed ID: 37959413
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review.
Pérez-Hernández JL; Arce-Salinas CA; Lehmann-Mendoza R; Torre-Delgadillo A; Castro-Narro GE; Cerda-Reyes E; Ramos-Gómez MV; Juárez-Chavez L; Dehesa-Violante M; Muñoz-Espinosa LE; Cisneros-Garza LE; Aiza-Haddad I; Velarde-Ruiz-Velasco JA; Contreras-Omaña R; García-Casarreal N; Carmona-Castañeda A; Higuera-De la Tijera F
Rev Gastroenterol Mex (Engl Ed); 2021 Jan; ():. PubMed ID: 33531165
[TBL] [Abstract][Full Text] [Related]
18. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.
Yang CC; Huang CF; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Kuo HT; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Tseng KC; Chen CY; Yu ML
Infect Dis Ther; 2024 Apr; ():. PubMed ID: 38679663
[TBL] [Abstract][Full Text] [Related]
19. Profile of Sofosbuvir and Velpatasvir Combination in the Treatment of Chronic Hepatitis C in Children and Adolescents: Current Evidence.
Brigham D; Narkewicz MR
Ther Clin Risk Manag; 2024; 20():1-7. PubMed ID: 38230373
[TBL] [Abstract][Full Text] [Related]
20. Evaluación del valor clínico y económico de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con hepatitis C crónica en España durante los últimos 5 años.
Esteban R; Hernández RD; Cantero H; Casado MÁ
Gastroenterol Hepatol; 2024 May; ():502199. PubMed ID: 38723771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
